Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features
As Outset has added features improving Tablo since the FDA first cleared it for use, it has now had to submit another 510(k) application to the FDA, thus limiting sales to acute facilities only.
Read the full article » | Posted 07-13-2022
Related Articles
- Nephrologist Dr. Roberto Collazo Shares New Treatments for Kidney Disease and ESKD Posted 12-11-2024
- Ellen Lukens from CMMI Presents on the Kidney Care Choices Model Posted 12-11-2024
- 2025 NKF Survey on Kidney Health Priorities Finds Home Dialysis is a Patient Priority Posted 12-11-2024
- FDA Correction on Baxter MiniCap Extended Life PD Transfer Set Posted 12-11-2024